High-dose GHRP-6: Moderate-high risk Why it's concerning: Significant appetite increase (can derail diet) Prolactin elevation (gynecomastia risk in sensitive individuals) Cortisol increase at high doses Water retention When it might be acceptable: Moderate doses (100-200mcg, not 300+mcg) Short-term use (8-12 weeks) If appetite increase isn't problematic Safer alternatives: Ipamorelin (no prolactin/cortisol increase) Lower GHRP-6 doses with careful monitoring Hexarelin: Higher risk than benefits justify Why it's problematic: Rapid desensitization (must cycle frequently) Cortisol and prolactin elevation Heart stress concerns Diminishing returns Limited use cases: Very short cycles (4 weeks maximum) Experienced users only With careful monitoring Better options: Ipamorelin for sustained results GHRP-2 for middle ground Synthetic growth hormone: Highest overall risk Why avoid: Complete shutdown of natural GH production Organ growth (hands, feet, jaw, internal organs) Insulin resistance Expensive Requires PCT (post-cycle therapy) Legal issues in most countries Only justified for: Medical growth hormone deficiency Under physician supervision Replacement doses, not supraphysiological Much safer alternatives: CJC-1295 + Ipamorelin stack Natural peptides that stimulate endogenous GH No shutdown, no PCT needed See peptides vs steroids and peptides vs SARMs for safety comparisons
It is a fundamental flaw that makes the results unreliable
10.1016/j.clpt.2006.09.003 Clin
Despite the health benefits of weight-loss interventions like nutritional counseling, bariatric surgery, and medications like GLP-1 receptor agonists, utilization of obesity-related healthcare remains extremely low, especially by populations that are most affected by obesity
25 Changing GIP Ile 17 to Ala massively lowered the insulinotropic effect
ShangCLiuZZhuYLuJGeCZhangCet alSARS-CoV-2 causes mitochondrial dysfunction and mitophagy impairment
